ANEBULO PHARMACEUTICALS, INC. Increase (Decrease) in Accounts Payable
ANEBULO PHARMACEUTICALS, INC. (ANEB) reported Increase (Decrease) in Accounts Payable of $330.69 thousand for the 6-month period ending 2025-12-31, per its 10-Q filed 2026-02-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-02-12
- ANEBULO PHARMACEUTICALS, INC. increase (decrease) in accounts payable for the quarter ending 2025-12-31 was -$52.68K, a 276.91% decline year-over-year.
- ANEBULO PHARMACEUTICALS, INC. increase (decrease) in accounts payable for the quarter ending 2025-09-30 was $383.36K, a 300.52% increase year-over-year.
- ANEBULO PHARMACEUTICALS, INC. increase (decrease) in accounts payable for the quarter ending 2025-06-30 was -$203.40K.
- ANEBULO PHARMACEUTICALS, INC. increase (decrease) in accounts payable for the quarter ending 2025-03-31 was $145.66K, a 119.89% increase year-over-year.
- ANEBULO PHARMACEUTICALS, INC. increase (decrease) in accounts payable for fiscal 2025 was $67.75K.
- ANEBULO PHARMACEUTICALS, INC. increase (decrease) in accounts payable for fiscal 2024 was -$378.12K, a 345.98% decline from fiscal 2023.
- ANEBULO PHARMACEUTICALS, INC. increase (decrease) in accounts payable for fiscal 2023 was $153.72K, a 43.23% decline from fiscal 2022.
- ANEBULO PHARMACEUTICALS, INC. increase (decrease) in accounts payable for fiscal 2022 was $270.78K, a 146.06% increase from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|
| 2025-12-31 | -$52.68K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-12 | $330.69K 10-Q · filed 2026-02-12 | $127.28K derived: sum of 3 quarters · filed 2026-02-12 | $272.94K derived: sum of 4 quarters · filed 2026-02-12 |
| 2025-09-30 | $383.36K 10-Q · filed 2025-11-13 | $179.96K derived: sum of 2 quarters · filed 2025-11-13 | $325.62K derived: sum of 3 quarters · filed 2025-11-13 | $355.40K derived: sum of 4 quarters · filed 2026-02-12 |
| 2025-06-30 | -$203.40K derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-29 | -$57.74K derived: sum of 2 quarters · filed 2025-09-29 | -$27.97K derived: sum of 3 quarters · filed 2026-02-12 | $67.75K 10-K · filed 2025-09-29 |
| 2025-03-31 | $145.66K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-05-13 | $175.44K derived: sum of 2 quarters · filed 2026-02-12 | $271.15K 10-Q · filed 2025-05-13 | $42.66K derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-12-31 | $29.78K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-12 | $125.49K 10-Q · filed 2026-02-12 | -$103.00K derived: sum of 3 quarters · filed 2026-02-12 | -$36.76K derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-09-30 | $95.72K 10-Q · filed 2025-11-13 | -$132.78K derived: sum of 2 quarters · filed 2025-11-13 | -$66.54K derived: sum of 3 quarters · filed 2025-11-13 | -$313.81K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | -$228.49K derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-29 | -$162.25K derived: sum of 2 quarters · filed 2025-09-29 | -$409.52K derived: sum of 3 quarters · filed 2025-09-29 | -$378.12K 10-K · filed 2025-09-29 |
| 2024-03-31 | $66.24K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-05-13 | -$181.03K derived: sum of 2 quarters · filed 2025-05-13 | -$149.63K 10-Q · filed 2025-05-13 | -$185.98K derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | -$247.27K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-02-14 | -$215.87K 10-Q · filed 2025-02-14 | -$252.22K derived: sum of 3 quarters · filed 2025-02-14 | -$27.88K derived: sum of 4 quarters · filed 2025-02-14 |
| 2023-09-30 | $31.40K 10-Q · filed 2024-11-13 | -$4.95K derived: sum of 2 quarters · filed 2024-11-13 | $219.40K derived: sum of 3 quarters · filed 2024-11-13 | $291.40K derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | -$36.36K derived: 10-K 12 month − 10-Q 9 month · filed 2024-09-25 | $187.99K derived: sum of 2 quarters · filed 2024-09-25 | $260.00K derived: sum of 3 quarters · filed 2024-09-25 | $153.72K 10-K · filed 2024-09-25 |
| 2023-03-31 | $224.35K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-05-15 | $296.36K derived: sum of 2 quarters · filed 2024-05-15 | $190.07K 10-Q · filed 2024-05-15 | $487.63K derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $72.01K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-02-13 | -$34.27K 10-Q · filed 2024-02-13 | $263.28K derived: sum of 3 quarters · filed 2024-02-13 | $303.61K derived: sum of 4 quarters · filed 2024-02-13 |
| 2022-09-30 | -$106.28K 10-Q · filed 2023-11-14 | $191.27K derived: sum of 2 quarters · filed 2023-11-14 | $231.60K derived: sum of 3 quarters · filed 2023-11-14 | -$219.27K derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $297.55K derived: 10-K 12 month − 10-Q 9 month · filed 2023-09-22 | $337.88K derived: sum of 2 quarters · filed 2023-09-22 | -$112.99K derived: sum of 3 quarters · filed 2023-09-22 | $270.78K 10-K · filed 2023-09-22 |
| 2022-03-31 | $40.33K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-05-11 | -$410.54K derived: sum of 2 quarters · filed 2023-05-11 | -$26.77K 10-Q · filed 2023-05-11 | $1.25K derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$450.88K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-02-10 | -$67.10K 10-Q · filed 2023-02-10 | -$39.08K derived: sum of 3 quarters · filed 2023-02-10 | -$41.53K derived: sum of 4 quarters · filed 2023-02-10 |
| 2021-09-30 | $383.77K 10-Q · filed 2022-11-10 | $411.79K derived: sum of 2 quarters · filed 2022-11-10 | $409.34K derived: sum of 3 quarters · filed 2022-11-10 | $327.41K derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $28.02K derived: 10-K 12 month − 10-Q 9 month · filed 2022-09-09 | $25.57K derived: sum of 2 quarters · filed 2022-09-09 | -$56.36K derived: sum of 3 quarters · filed 2022-09-09 | $110.05K 10-K · filed 2022-09-09 |
| 2021-03-31 | -$2.45K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-05-11 | -$84.38K derived: sum of 2 quarters · filed 2022-05-11 | $82.03K 10-Q · filed 2022-05-11 | |
| 2020-12-31 | -$81.93K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-02-11 | $84.48K 10-Q · filed 2022-02-11 | ||
| 2020-09-30 | $166.41K 10-Q · filed 2021-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |